) exacerbated respiratory disease are terms for a disorder commonly described as affecting adults aged >30 y. With this perception, ibuprofen was administered for postoperative pain management to a 17-year-old boy with allergic rhinitis and previous severe asthma (at a time when well controlled), who then had a severe asthma exacerbation. Analysis of the literature in response to this case highlights four points: 1) NSAID-exacerbated asthma is not only a disorder of adults; it occurs in up to of 2% in asthmatic children, approaching probably 30% in older children with severe asthma and nasal disease. 2) The asthmatic reaction is dose-dependent and can occur with sub-therapeutic doses. Oral NSAID/aspirin challenge should be conducted in an environment where a severe asthma exacerbation can be appropriately managed.
Aspirin-sensitive asthma, aspirin-intolerant asthma, and most recently, aspirin-(or non-steroidal antiinflammatory drug [NSAID]) exacerbated respiratory disease (AERD/NSAID-ERD) are multiple terms for the same disorder [1] [2] [3] . Previously, AERD was understood to be a disease affecting adults 4 , usually females, commonly in their third to fourth decades 2,5 . Based upon this perception, a male asthmatic teenager who recently presented was given therapeutic ibuprofen for day surgery analgesia, following which he had a severe asthma exacerbation. High crosssensitivity exists between ibuprofen and aspirin for AERD and ibuprofen has been implicated in previous adult case reports 1 . AERD has also been reported to occur in children 1, 2 . There has previously been a single report of ibuprofen-associated exacerbation of asthma in a young child 6 .
CASE REPORT
A 17-year-old 47 kg male asthmatic presented for elective inguinal hernia repair. In his early teens he had regular emergency department presentations and five hospital admissions for asthma, including three intensive care unit (ICU) stays. Previously described as a brittle asthmatic, he had often required week-or month-long courses of oral steroids every few months. His asthma was managed at a tertiary paediatric hospital by a respiratory paediatrician. He did not routinely perform peak flow rate (PFR) readings as part of his management, and had not had pulmonary function tests (PFTs) performed recently. However, for several months prior to surgery he had been well controlled on inhaled steroids (fluticasone propionate: Flixotide (Allen & Hanbury) 2 puffs b.d.) and had not required oral steroids and had no emergency department presentations or admissions. He had significantly reduced his β-adrenergic agonist use, requiring salbutamol via metered-dose inhaler on only two recent occasions for exercise. This was in contrast to 12 months earlier when he had required salbutamol frequently to complete exercise, and for several days during asthma exacerbations. Leading up to surgery, he reported no recent infective respiratory symptoms, and both he and his physician described his asthma as "the best it had ever been".
In common with adult cases of aspirin-sensitive asthma, he had a past history of poorly responsive allergic rhinitis. He had not been previously diagnosed with nasal polyps, but was due for ear, nose and throat specialist review. At the preoperative anaesthetic consultation he had poor nasal patency, but his chest was clear to auscultation. He and his mother were uncertain if he had received aspirin or NSAIDs in the past. In discussing postoperative pain control, the patient expressed keenness to avoid opioids and their constipating effects. Consequently, he was prescribed ibuprofen with the plan to administer the first dose under observation in hospital.
He had an uncomplicated intravenous anaesthetic induction with midazolam and propofol. Anaesthesia was maintained with nitrous oxide and isoflurane in oxygen with spontaneous ventilation through a laryngeal mask airway. He had a unilateral ilioinguinal/ iliohypogastric nerve block and groin infiltration with bupivacaine 0.5% 12 ml. Antibiotics were not administered. His intraoperative course and initial recovery in the post-anaesthesia care unit (PACU) were uneventful.
Two hours later, in the step-down post-PACU area he was given a dose of ibuprofen 400 mg (~10 mg/kg) orally for anticipatory pain control. Fifteen minutes later he began to wheeze, self-initiating eight salbutamol metered-dose inhaler (MDI) puffs via spacer. However, his symptoms worsened over the next 30 minutes with increased respiratory effort, reduced ability to speak, and oxygen saturations of 90% on 8 litres oxygen via face (Hudson) mask. On review, he was noted to be "grey", without any periorbital oedema or facial redness, and with no audible air entry on chest auscultation. As per the current recommendations for the management of an acute asthmatic exacerbation (hospital and pharmacopoeia guidelines for children over six years of age), 12 salbutamol MDI puffs via spacer were repeated. No benefit was attained and subsequently salbutamol 5 mg by nebuliser and intravenous (IV) dexamethasone 8 mg therapy were given. Despite three nebulisers, his distress increased with agitation and evident status asthmaticus. Consequently IV salbutamol was administered in titrated boluses (250 µg×2 and 500 µg×1). (These doses of 5-10 µg/kg IV are as used in Victoria for children and adults by ambulances and adult emergency departments.) This was less than this institution's intensive care/pharmacopoeia recommended loading of 5 µg/kg/minute over 60 minutes and then infusion of 1 µg/kg/minute 7 . The patient required continuous nebulisers (9×5 mg) for 1 hour and 20 minutes and then spaced to half-hourly (1 nebuliser) and then hourly (2 further nebulisers). His last nebuliser was required about five hours after the ibuprofen dose. He was admitted for overnight observation to a high dependency unit. Unfortunately peak flow readings were not measured. During this time, no further nebulisers were required and his chest remained clear. For pain control, he received a paracetamol/codeine combination. He was discharged the next morning without a further dose of IV or oral steroids. He experienced no further asthma symptoms that week on his usual prophylactic inhalers.
DISCUSSION
The natural history of AERD or NSAID-ERD is usually age-related with allergic rhinosinusitis occurring in the late third decade, preceding asthma development by about two years. Polyps (present in greater than 60% of aspirin-sensitive adults) and aspirin sensitivity develop even later (about 4 years, i.e. by mid 4th decade) 1,2,5 . AERD is now the preferred terminology incorporating the generalized respiratory mucosal process and superseding the term "aspirin triad" (aspirin "allergy" [angio-oedema, urticaria and rhinitis], nasal polyps and asthma). Following this case, a literature search was performed that revealed that aspirin/NSAID intolerance has also been reported, although uncommonly, in children, and rarely in infants 1,2,6 .
The prevalence of asthma itself in adults varies from 7 to 10%, and is twice this in children (20%). AERD prevalence is variably reported due to differences in definitions (i.e. survey questions vs decrease in peak flow rates) and methodology 1 . Adult AERD rates are variably quoted as 0.7 to 4% of asthmatics 1-3 , as 11% in Australian asthmatics 8 , rising to 14 to 33% when asthma is associated with nasal polyps 1,2 , and 28% when associated with severe atopic adult asthma 1 . While paediatric reports from the late 1980s suggest the incidence in asthmatic children is less than 2% [based upon patient reported history], others report incidences of 0 to 28% following aspirin oral challenge 2 . The variation in reported incidences of paediatric AERD possibly reflects different age group selection (i.e. higher rates when challenging the older child with more severe asthma and nasal disease) 1, 2 .
With regard to NSAIDs other than aspirin, reported cross-sensitivity between aspirin and ibuprofen for AERD in adults is 100% 1 . Both these agents are cyclooxygenase [COX]-1 preferential (defined as COX1: COX 2 ratios >1 for inhibition of 50% of the enzyme activity in blood in vitro: aspirin has a ratio of 3.12 and ibuprofen 1.69) 7 . Reactions to NSAIDs other than aspirin make up 18% of those selfreported by adult AERD patients 2 . Levy reviews 11 case reports in predominantly adult females aged 20 to 65 years, three of whom died following oral ibuprofen (200-400 mg), three others reacting to alternative "profens" and two following eye application 1 .
In young children, only a single case of NSAID/ ibuprofen exacerbated asthma in a boy aged two has been reported previously 6 . This child had mild episodic asthma ("responsive" to short courses of oral salbutamol) and received ibuprofen (dose not documented) for fever management during a concurrent viral upper respiratory tract infection (URTI). The viral URTI offers an alternative explanation for his asthma exacerbation. The resolution of symptoms after cessation of the ibuprofen could be attributed to oral steroid use or natural disease course, as he did not subsequently have a confirmatory oral challenge. Ibuprofen has since been reported as safe for fever management in 1247 paediatric asthmatics (aged 1 to 12 years, where patients received between six and ten therapeutic doses, acknowledging that patients with known sensitivity were excluded) 10 . This data, combined with the frequency of NSAID administration in both the community and in hospitals, and the fact that there are no prior reports of NSAID-ERD in the paediatric post-surgical setting, suggests that AERD is indeed rare in young children, including those with episodic wheeze. AERD is probably more frequent in a subgroup of teenagers with moderate to severe asthma and nasal disease, and has been estimated as follows 2 : teenage asthma prevalence of around 10%, with less than one third with severe disease, and with one third of this severe group at risk of AERD. This equates to an approximate 1% incidence. The severity of this patient's exacerbation should induce caution amongst paediatric anaesthetists and pain management specialists when prescribing NSAIDs in patients at risk.
The aetiologies of aspirin allergy and AERD are not well understood. AERD is thought to stem from COX enzyme inhibition (suggested by some authors as specifically COX-1) 2 altering ratios of protective prostaglandins versus bronchoconstricting leukotrienes 11 . COX-2 specific inhibitors have been described as both causative 1 or non-triggering in AERD [12] [13] [14] [15] and beneficial 1, 10, 15 in paediatric and adult asthma symptom reduction. Clinical research in directed leukotriene therapy of asthma is underway 17 . Additionally, AERD patients' urinary and leucocyte leukotriene and prostaglandin (LTE 4 , LTC 4 , lipoxinA 4 , 15HETE) release has been studied 1, 17 . Levels are unchanged with COX-2 selective celecoxib administration. Surprisingly they are altered by naproxen [COX 1:2 ratio of 0.88 9 ] but not COX-1 preferential indomethacin [COX-1:2 ratio of 1.78 9 ] 17 . Clearly, the underlying pathological mechanisms have not been fully elucidated.
Aspirin oral challenge (over nasal and inhalational challenge) is the current gold diagnostic standard for AERD, with graded dosing to 650 mg. No in vitro test is available and skin testing is not useful 1, 5, 18 . The oral aspirin dose inducing asthma is sub-analgesic (usual mean 60 mg, range 30-150 mg) with 39% intraindividual variability to an index challenge. The response severity is dose-dependent. A positive response is defined as greater than 20% reduction of forced expiratory volume in 1 s (FEV 1 )±naso-ocular (and skin) reaction occurring within less than three hours of administration. Both signs are present in approximately 66% of positive adult patient challenges; bronchospasm occurs alone in approximately 6% 2 . These manifestations may be modified by therapy with oral or inhaled steroids, leukotrienesuppression, or cromolyn. Despite the presence of asthma-modifying therapy, symptoms will manifest once therapeutic aspirin doses (generally >300 mg) are reached. The oral test is appropriate for patients with stable and mild to moderate asthma (i.e. FEV 1 greater than 70% predicted with only 10% variability). An oral aspirin challenge should be performed in a hospital with high dependency/intensive care facilities able to treat a severe asthma exacerbation. The rapid development of our patient's status asthmaticus highlights this need. Notably, nasal challenge with lysine-aspirin is preferable in severe asthmatics, as reduction in pulmonary function tests has not been reported 2 . Patent nasal flow is, however, necessary. The positive predictive value in a patient reporting positive reaction on history is greater than 97%. There is, however, a false negative rate and negative predictive value of only 77% 2 .
The teenage boy presented here received a therapeutic dose of ibuprofen (8.7 mg/kg; the recommended analgesic dose is 5-10 mg/kg, 6 hourly). The patient, who was at the time compliant with inhaled steroid therapy, had possible nasal without ocular reaction in association with severe life-threatening asthma exacerbation occurring 15 minutes (peaking at 45 minutes) following ingestion. This exacerbation occurred 2 hours following cessation of administration of oxygen therapy or dry anaesthetic gases, in an open plan, non-carpeted surgical day suite. This severe exacerbation had rapid onset and occurred at a time when he was otherwise well controlled with no symptoms or signs present pre-, intra-or postoperatively prior to ibuprofen administration. Differential diagnoses for this exacerbation are ibuprofen-induced, or a spontaneous exacerbation because he was a known brittle asthmatic. His condition was not consistent with anaphylaxis. The temporal association with ibuprofen is strong. In order to confirm NSAID sensitivity, as this patient's asthma was severe, nasal provocation testing should be considered. This requires adequate nasal patency to be performed successfully. He has declined confirmatory challenge and has been advised to avoid NSAIDs and aspirin.
Paracetamol (COX-1:2 ratio of 0.28 9 ) at clinicallyused "high" doses of 1-1.2 g 1 and the common United States dose of 650 mg 12 has been implicated in a small subgroup patients with AERD. Despite this, Levy's review suggests doses of 650 mg are safe 1 . This widely used agent can therefore be classified as "probably safe". COX-2 selective agents were developed to offer similar analgesic efficacy with reduced adverse effect profiles over the non-selective NSAIDs 19 . Unfortunately, the COX-2 selective inhibitors, celecoxib and rofecoxib, were initially reported as inducing bronchospasm/asthma in 70 United Kingdom patients 1 . Countering these, three recent studies [12] [13] [14] (181 patients) and a meta-analysis of four studies (with one study in common of 60 patients 12 ; 173 patients total) 16 have used COX-2 selective agents safely in aspirin/NSAID-susceptible adult patients. These studies were placebo-controlled using therapeutic doses of celecoxib (200 mg) 12, 13, 16 and rofecoxib (25-50 mg) 14, 16 (~10 times more COX-2 selective than celecoxib 21 ) in patients with moderate 12, 13, 16 to severe 12, 16 asthma, and varying grades of NSAID sensitivity. Additionally, two earlier rofecoxib studies of 12.5 mg are quoted 14 with no reactions in aspirin-sensitive patients. Tramadol and opioids have not been implicated in AERD and are of similar analgesic potency to NSAIDs. Non-histamine releasing analgesics may be preferable if a patient has severe atopy or reports asthma exacerbation with morphine.
In determining post-marketing safety of a drug with a rarely seen complication, conflict arises in the interpretation of a few case reports (that may or may not be a true association) in the context of widespread use of the drug, compared with reported safe use in a small number of trials with small patient numbers that are performed in well-defined at-risk patients. The current consensus therefore is that COX-2s are "probably safe" in aspirin-exacerbated respiratory disease. The same conflict arises for recommendations for ibuprofen use in young children where one prior case report of "associated" asthma in a 2-year-old competes with a larger scale report of safe use of 5-10 mg/kg in 1247 asthmatic children (less than 12 y) 10 and a report of a possible benefit of NSAIDs 10,15 (and COX-2 selective inhibitors) 15 in paediatric asthma.
NSAID-or aspirin-exacerbated respiratory disease is therefore not only a disease of middle-aged adults but also occurs in teenagers, albeit infrequently, and even less commonly in younger children. The aspirinexacerbated respiratory disease at-risk group includes patients of any age with moderate to severe asthma and nasal disease (chronic, particularly refractory, rhinosinusitis and/or nasal polyps). Thus, the recommendation is to avoid therapeutic use of nonselective COX-1 preferential NSAIDs in those patients either reporting sensitivity (where around 85% of these patients will indeed have aspirinexacerbated respiratory disease 2 ) or who are suspected at risk (acknowledging that two out of three of these patients will not be NSAID-sensitive 1 ). The latter group can be considered for later aspirin challenge. Mild asthmatics and the younger child with episodic wheeze can probably tolerate NSAID therapy (and may indeed experience symptom improvement). Tramadol and opioids are reported to be safe analgesic alternatives. COX-2 selective inhibitors and paracetamol can probably be used when strongly indicated with appropriate monitoring of high-risk patients. If other safe analgesic or antipyretic alternatives are ineffective or not tolerated, in-hospital initiation of these agents or COX-1 preferential NSAIDs at sub-therapeutic doses (as the reaction is dose-dependent) may be warranted.
